<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451151</url>
  </required_header>
  <id_info>
    <org_study_id>CA-0004542</org_study_id>
    <nct_id>NCT01451151</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)</brief_title>
  <official_title>A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aderans Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aderans Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to&#xD;
      induce hair growth in male and female subjects with hair loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in hair number</measure>
    <time_frame>51 weeks post-injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in hair width</measure>
    <time_frame>51 weeks post-injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of any treatment benefit</measure>
    <time_frame>51 weeks post-injection</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <condition>Male Pattern Baldness</condition>
  <condition>Female Pattern Baldness</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous cultured dermal and epidermal cells</intervention_name>
    <description>A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.</description>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female volunteers 18 to 65 years old, inclusive&#xD;
&#xD;
          -  Hair loss consistent with â‰¥ Grade III-Vertex, IV, VA, V, and VI, based on&#xD;
             Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the&#xD;
             vertex circle.&#xD;
&#xD;
          -  Able to provide informed consent after risks and benefits of the study have been&#xD;
             explained.&#xD;
&#xD;
          -  Be willing to undergo all study procedures.&#xD;
&#xD;
          -  Ability to communicate effectively with study personnel.&#xD;
&#xD;
          -  Have no clinically significant disease or abnormal laboratory evaluations taken at the&#xD;
             screening visit.&#xD;
&#xD;
          -  Agree to abstain from use of any hair growth affecting oral or topical medication&#xD;
             including over the counter and herbal medications, minoxidil, finasteride or&#xD;
             dutasteride during the course of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to DMEM/F-12 or any component of the study material.&#xD;
&#xD;
          -  Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin&#xD;
             sulfate.&#xD;
&#xD;
          -  Subjects who have used minoxidil or any oral or topical medication including over the&#xD;
             counter and herbal medications for the treatment of hair loss within 6 months of study&#xD;
             screening, or finasteride or dutasteride within 12 months of study screening.&#xD;
&#xD;
          -  A history of drug or alcohol abuse within 1 year of study enrollment.&#xD;
&#xD;
          -  Paricipation in any other investigational study within 30 days or six half lives of&#xD;
             its biologic activity, whichever is longer, before the scalp excision visit(s), and&#xD;
             during the time enrolled in this study.&#xD;
&#xD;
          -  Clinically significant medical or psychiatric illness currently or within 30 days of&#xD;
             study screening as determined by the investigator.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory parameters.&#xD;
&#xD;
          -  A positive result at screening for human immunodeficiency virus (HIV 1 or 2),&#xD;
             Hepatitis B or C, HTLV I/II.&#xD;
&#xD;
          -  Clinically significant dermatologic condition in donation or study areas.&#xD;
&#xD;
          -  Prior surgery in the donor or study areas.&#xD;
&#xD;
          -  Insufficient hair or scarring in the donor area that might impact cell growth.&#xD;
&#xD;
          -  Any disease or condition (medical or surgical) that, in the opinion of the&#xD;
             investigator, might compromise hematologic, cardiovascular, pulmonary, renal,&#xD;
             gastrointestinal, hepatic, or central nervous system function; or any condition that&#xD;
             would place the subject at increased risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Axis Clinical Trials, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials, Inc.</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgenetic Alopecia</keyword>
  <keyword>Male Pattern Baldness</keyword>
  <keyword>Female Pattern Baldness</keyword>
  <keyword>Hair Loss</keyword>
  <keyword>Baldness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

